103 related articles for article (PubMed ID: 28429090)
41. Nontherapeutic celiotomy incidence is not affected by volume of pancreaticoduodenectomy for pancreatic adenocarcinoma.
Toomey P; Childs C; Luberice K; Ross S; Rosemurgy A
Am Surg; 2013 Aug; 79(8):781-5. PubMed ID: 23896244
[TBL] [Abstract][Full Text] [Related]
42. Palliative pancreaticoduodenectomy in pancreatic and periampullary adenocarcinomas.
Wang SE; Shyr YM; Su CH; Chen TH; Wu CW
Pancreas; 2012 Aug; 41(6):882-7. PubMed ID: 22286381
[TBL] [Abstract][Full Text] [Related]
43. Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Pugalenthi A; Protic M; Gonen M; Kingham TP; Angelica MI; Dematteo RP; Fong Y; Jarnagin WR; Allen PJ
J Surg Oncol; 2016 Feb; 113(2):188-93. PubMed ID: 26678349
[TBL] [Abstract][Full Text] [Related]
44. Impact of portal vein invasion and resection length in pancreatoduodenectomy on the survival rate of pancreatic head cancer.
Kurihara C; Yoshimi F; Sasaki K; Nakao K; lijima T; Kawasaki H; Nagai H
Hepatogastroenterology; 2013 Oct; 60(127):1759-65. PubMed ID: 24634947
[TBL] [Abstract][Full Text] [Related]
45. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
46. Pancreaticoduodenectomy with vascular resection: margin status and survival duration.
Tseng JF; Raut CP; Lee JE; Pisters PW; Vauthey JN; Abdalla EK; Gomez HF; Sun CC; Crane CH; Wolff RA; Evans DB
J Gastrointest Surg; 2004 Dec; 8(8):935-49; discussion 949-50. PubMed ID: 15585381
[TBL] [Abstract][Full Text] [Related]
47. Severe Jaundice Increases Early Severe Morbidity and Decreases Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma.
Sauvanet A; Boher JM; Paye F; Bachellier P; Sa Cuhna A; Le Treut YP; Adham M; Mabrut JY; Chiche L; Delpero JR;
J Am Coll Surg; 2015 Aug; 221(2):380-9. PubMed ID: 26206638
[TBL] [Abstract][Full Text] [Related]
48. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis.
Kamarajah SK; Burns WR; Frankel TL; Cho CS; Nathan H
Ann Surg Oncol; 2017 Jul; 24(7):2023-2030. PubMed ID: 28213792
[TBL] [Abstract][Full Text] [Related]
49. Identification of prognostic factors associated with early mortality after surgical resection for pancreatic cancer--under-analysis of cumulative survival curve.
Takamori H; Hiraoka T; Kanemitsu K; Tsuji T; Hamada C; Baba H
World J Surg; 2006 Feb; 30(2):213-8. PubMed ID: 16425074
[TBL] [Abstract][Full Text] [Related]
50. Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss.
Kazanjian KK; Hines OJ; Duffy JP; Yoon DY; Cortina G; Reber HA
Arch Surg; 2008 Dec; 143(12):1166-71. PubMed ID: 19075167
[TBL] [Abstract][Full Text] [Related]
51. Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer.
Han SS; Park SJ; Kim SH; Cho SY; Kim YK; Kim TH; Lee SA; Woo SM; Lee WJ; Hong EK
Pancreas; 2012 Jan; 41(1):102-6. PubMed ID: 21775914
[TBL] [Abstract][Full Text] [Related]
52. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
[TBL] [Abstract][Full Text] [Related]
53. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
[TBL] [Abstract][Full Text] [Related]
54. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Raut CP; Tseng JF; Sun CC; Wang H; Wolff RA; Crane CH; Hwang R; Vauthey JN; Abdalla EK; Lee JE; Pisters PW; Evans DB
Ann Surg; 2007 Jul; 246(1):52-60. PubMed ID: 17592291
[TBL] [Abstract][Full Text] [Related]
55. Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Tingle SJ; Moir JA; White SA
World J Gastrointest Pathophysiol; 2015 Nov; 6(4):235-42. PubMed ID: 26600982
[TBL] [Abstract][Full Text] [Related]
56. Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis.
Beg MS; Gupta A; Sher D; Ali S; Khan S; Gao A; Stewart T; Ahn C; Berry J; Mortensen EM
Am J Clin Oncol; 2018 Aug; 41(8):766-771. PubMed ID: 28079594
[TBL] [Abstract][Full Text] [Related]
57. IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone.
Kast RE
Oncoscience; 2024; 11():15-31. PubMed ID: 38524376
[TBL] [Abstract][Full Text] [Related]
58. Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC).
Pervin J; Asad M; Cao S; Jang GH; Feizi N; Haibe-Kains B; Karasinska JM; O'Kane GM; Gallinger S; Schaeffer DF; Renouf DJ; Zogopoulos G; Bathe OF
Front Genet; 2023; 14():1282824. PubMed ID: 38028629
[No Abstract] [Full Text] [Related]
59. Angiotensin blockade therapy and survival in pancreatic cancer: a population study.
Keith SW; Maio V; Arafat HA; Alcusky M; Karagiannis T; Rabinowitz C; Lavu H; Louis DZ
BMC Cancer; 2022 Feb; 22(1):150. PubMed ID: 35130875
[TBL] [Abstract][Full Text] [Related]
60. Angiotensin II receptor blockers and oral squamous cell carcinoma survival: A propensity-score-matched cohort study.
Wu CN; Wu SC; Chen WC; Yang YH; Chin JC; Chien CY; Fang FM; Li SH; Luo SD; Chiu TJ
PLoS One; 2021; 16(12):e0260772. PubMed ID: 34855858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
